ApicHope Pharmaceutical Group Co., Ltd. (300723.SZ)
- Previous Close
39.18 - Open
38.17 - Bid 39.84 x --
- Ask 39.86 x --
- Day's Range
38.73 - 40.50 - 52 Week Range
12.74 - 42.42 - Volume
10,807,134 - Avg. Volume
12,317,171 - Market Cap (intraday)
17.991B - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
-- - EPS (TTM)
-1.29 - Earnings Date --
- Forward Dividend & Yield 0.21 (0.53%)
- Ex-Dividend Date Jun 3, 2024
- 1y Target Est
40.26
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical drugs. Its pediatric medicines include fuganlin and yiqi jianpi oral liquid, carboxymestrine oral solution, and xiaoer kechuanling oral liquid products; and clindamycin hydrochloride palmitate dispersible tablet, acetylguitaricin dry suspension, qinxiangqingjie oral liquid, levocetirizine hydrochloride drop, epstein hydrochloride granule, clindamycin hydrochloride palmitate granule, clindamycin hydrochloride for injection, clindamycin phosphate injection, ambroxol hydrochloride drop, montelukast sodium granule, acyclovir for injection, and oseltamivir phosphate capsule products. The company's chronic disease drugs comprise hepatocyte growth stimulating hormone and pentoxifylline for injections, kangshen granules, uqingshu granules, shenbai lotion products, compound monoammonium glycyrrhizinate S and lansoprazole for injections, houttuynia sodium tablets, omeprazole sodium and bromhexine hydrochloride for injections, huixinkang tablets, amlodipine benzenesulfonate dispersible tablets, yanhunin and sodium ferulate for injections, cyclic adenosine phosphate and ambroxol hydrochloride for injections, valsartan amlodipine tablets, and nifedipine controlled release tablets, as well as tricorutin, aceglutamide, vinpocetine, and doxofylline for injections. In addition, it offers compound xiangrui water, yinhuang oral liquid, and xiongdan chuanbei oral liquid products; venlafaxine hydrochloride sustained-release capsules; and levofloxacin hydrochloride, sodium ozagrel, brain protein hydrolysate, and ganciclovir for injections. The company was formerly known as ApicHope Pharmaceutical Co., Ltd and changed its name to ApicHope Pharmaceutical Group Co., Ltd. in December 2024. ApicHope Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Guangzhou, China.
www.apichope.com1,484
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 300723.SZ
View MorePerformance Overview: 300723.SZ
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300723.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300723.SZ
View MoreValuation Measures
Market Cap
17.99B
Enterprise Value
19.68B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.94
Price/Book (mrq)
9.30
Enterprise Value/Revenue
16.34
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-48.49%
Return on Assets (ttm)
-5.34%
Return on Equity (ttm)
-26.00%
Revenue (ttm)
1.2B
Net Income Avi to Common (ttm)
-583.96M
Diluted EPS (ttm)
-1.29
Balance Sheet and Cash Flow
Total Cash (mrq)
817.08M
Total Debt/Equity (mrq)
125.98%
Levered Free Cash Flow (ttm)
-604.17M